Sharekhan's research report on Biocon
Biocon registered mixed operating performance in Q2 with revenue growing in strong double digits, while higher cost pressures led to a decline in PAT. Revenue grew by 26% y-o-y to Rs. 2,319.7 crore, driven by strong 34% y-o-y growth in the biologics segment, 25.9% y-o-y growth in the research services segment, and 17.5% y-o-y growth in the generic segment. EBIDTA margin fell by 399 BPS to 20.3%; PAT was down by 10% y-o-y to Rs. 205.7 crore. Consolidation of Viatris and the strategic vaccines alliance with Serum Institute will add to growth of the Biosimilars business in H2FY2023. Margins might remain lower due to higher R&D cost.
Outlook
The stock is currently trading at 32.9/21.6x its FY2023/FY2024E earnings. We maintain our Buy rating on the stock with a revised PT of Rs. 340.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!